Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection.
Previously, we showed that long-circulating polyethylene glycol (PEG)-liposomes are cleared rapidly from the circulation when injected repeatedly in the same animal. In this article, we describe the effects of PEG-coating, the circulation time, the lipid dose, and the presence of encapsulated doxorubicin on the pharmacokinetics upon repeated injection in rats. Furthermore, the role of liver and splenic macrophages was investigated. Liposomes without PEG-coating also showed the so-called "enhanced clearance effect": blood levels at 4 h post injection decreased from 62.8 +/- 13.7% of injected dose (%ID) after the first injection to 0.54 +/- 0.21%ID after the second injection. This decrease was independent of the circulation time of the first dose. Decreasing the first lipid dose of PEG-liposomes to 0.05 micromol/kg still led to enhanced clearance of a second dose of 5 micromol/kg. No changes in pharmacokinetics were observed when the second dose was 50 micromol/kg. When hepatosplenic macrophages were depleted, no enhanced clearance of repeated liposome injections was observed. A dose of doxorubicin containing PEG-liposomes (Doxil), injected 1 week after injection of empty PEG-liposomes, was cleared rapidly from the circulation in rats. Our results indicate that hepatosplenic macrophages play an essential role in the enhanced clearance effect and that the change in pharmacokinetic behavior upon repeated injection is a general characteristic of liposomes, unrelated to the presence of PEG. Therefore, these findings may have a considerable impact on the clinical application of liposomal formulations that are administered repeatedly.
Laverman
P
P
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands. p.laverman@nugen.azn.nl
Carstens
M G
MG
Boerman
O C
OC
Dams
E T
ET
Oyen
W J
WJ
van Rooijen
N
N
Corstens
F H
FH
Storm
G
G
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics; D004337:Drug Carriers; D005079:Excipients / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007205:Indium Radioisotopes; D008081:Liposomes; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D013667:Technetium; D014018:Tissue Distribution
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D005079:Excipients; D007205:Indium Radioisotopes; D008081:Liposomes; D011092:Polyethylene Glycols; D013667:Technetium; D004317:Doxorubicin